2022
Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm
Gupta A, Department of Medicine Y, Afinogenova Y, Podoltsev N, Danve A, Section of Rheumatology A, Section of Hematology D. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. European Journal Of Rheumatology 2022, 9: 215-216. PMID: 35156633, DOI: 10.5152/eurjrheum.2022.21097.Peer-Reviewed Case Reports and Technical NotesMyeloid neoplasmsBiologic disease-modifying agentsTumor necrosis factor inhibitorsTyrosine kinase inhibitor imatinibNecrosis factor inhibitorsAutoimmune rheumatic diseasesDisease-modifying agentsKinase inhibitor imatinibTyrosine kinase inhibitorsMiddle-aged malesRheumatic diseasesFactor inhibitorsPatients' qualityFavorable outcomeHematologic malignanciesInhibitor imatinibBeta rearrangementInfliximabConcurrent useKinase inhibitorsCancer diagnosisPatientsNeoplasmsAppropriate casesInhibitors
2020
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.
Gerds A, Gotlib J, Bose P, Deininger M, Dunbar A, Elshoury A, George T, Gojo I, Gundabolu K, Hexner E, Hobbs G, Jain T, Jamieson C, Kuykendall A, McMahon B, Mohan S, Oehler V, Oh S, Pardanani A, Podoltsev N, Ranheim E, Rein L, Salit R, Snyder D, Stein B, Talpaz M, Thota S, Vachhani P, Wadleigh M, Walsh K, Ward D, Bergman M, Sundar H. Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1248-1269. PMID: 32886902, DOI: 10.6004/jnccn.2020.0042.Peer-Reviewed Original ResearchConceptsMyeloid/lymphoid neoplasmsWHO classificationMLN-EoFusion geneEosinophilic disordersNCCN Clinical Practice GuidelinesRearrangement of PDGFRATyrosine kinaseABL1 rearrangementsClinical practice guidelinesLymphoid neoplasmsNCCN GuidelinesDysregulated tyrosine kinasePeripheral bloodPCM1-JAK2Organ damageABL1 geneNonneoplastic conditionsNeoplasmsEosinophiliaHeterogeneous groupFLT3Practice guidelinesNCCNABL1
2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal Of The National Comprehensive Cancer Network 2015, 13: 424-34. PMID: 25870379, PMCID: PMC8161684, DOI: 10.6004/jnccn.2015.0058.Peer-Reviewed Original ResearchConceptsMyeloproliferative neoplasmsClassical Philadelphia chromosome-negative myeloproliferative neoplasmsJAK1/JAK2 inhibitor ruxolitinibPrognostic scoring systemHematologists/oncologistsPhiladelphia chromosome-negative myeloproliferative neoplasmsJAK2 inhibitor ruxolitinibQuality of lifeCytoreductive agentsSymptom burdenVascular eventsInhibitor ruxolitinibPolycythemia veraDiagnostic criteriaEssential thrombocythemiaDisease pathogenesisFirst treatmentScoring systemNovel therapeuticsMyelofibrosisCALR mutationsMolecular diagnosisNeoplasms
2010
Overview of the Lymphoid Neoplasms
Podoltsev N, Lacy J, Vose J. Overview of the Lymphoid Neoplasms. 2010, 3-39. DOI: 10.1007/978-1-4419-7668-0_1.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaHodgkin's lymphomaPathogenesis of lymphomaHistologic featuresEtiologic factorsCommon subtypeWHO classificationTreatment outcomesCell neoplasmsClinical aspectsClinical groupingLymphoid malignanciesLymphoma pathogenesisLymphoid cellsLymphoid neoplasmsNormal lymphocytesLymphomaImmune systemDistinct subtypesNeoplasmsLymphocyte developmentSecond portionPathogenesisSubtypesGenetic events